北海康成-B(01228)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01228 北海康成-B

未开盘 08-06 16:08:33

2.150

+0.090

+4.37%

最高2.175	最低2.000	成交量480.10万
今开2.095	昨收2.060	日振幅8.50%
总市值12.84亿	流通市值12.84亿	总股本5.97亿
成交额982.84万	换手率0.80%	流通股本5.97亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01228","market":"HK","secType":"STK","nameCN":"北海康成-B","latestPrice":2.15,"timestamp":1786003713790,"preClose":2.06,"halted":0,"volume":4801000,"delay":0,"changeRate":0.04368932038834945,"floatShares":597000000,"shares":597000000,"eps":0.03,"marketStatus":"未开盘","change":0.09,"latestTime":"08-06 16:08:33","open":2.095,"high":2.175,"low":2,"amount":9828355,"amplitude":0.084951,"askPrice":2.15,"askSize":4000,"bidPrice":2.135,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":0.027,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786066200000},"marketStatusCode":0,"adr":0,"listingDate":1639065600000,"exchange":"SEHK","adjPreClose":2.06,"openAndCloseTimeList":[[1785979800000,1785988800000],[1785992400000,1786003200000]],"volumeRatio":1.164715,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01228","defaultTab":"news","newsList":[{"id":"1105365375","title":"北海康成-B 2026年7月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1105365375","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105365375?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:41","pubTimestamp":1786005698,"startTime":"0","endTime":"0","summary":"2026年8月6日，北海康成製藥有限公司公布截至2026年7月31日止月份的证券变动月报表。公告显示，公司本月未新增发行、购回或注销股份，股本结构整体维持稳定。报告期内的法定/注册股本维持在5,000,000,000股，面值为每股0.00001美元，注册股本总额约为50,000美元。根据公告，北海康成-B的首次公开发售后购股权计划在月末结存的股份期权数量为19,798,637份。北海康成-B表示将继续严格遵守香港联交所《上市规则》及其他相关法规规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657071571","title":"北海康成-B(01228.HK)：Richard Arthur Moscicki获委任为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2657071571","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657071571?lang=zh_cn&edition=full","pubTime":"2026-08-06 06:19","pubTimestamp":1785968393,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01228","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167564454","title":"北海康成-B（01228）公布董事会及三大专门委员会组成","url":"https://stock-news.laohu8.com/highlight/detail?id=1167564454","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167564454?lang=zh_cn&edition=full","pubTime":"2026-08-06 06:16","pubTimestamp":1785968212,"startTime":"0","endTime":"0","summary":"2026年8月5日，北海康成制药有限公司披露董事名册及董事在各专门委员会中的职能分工。本次公告未包含任何财务数据或业务经营指标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143484451","title":"北海康成-B（01228）：独立董事调整，Richard Arthur Moscicki 8月5日加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1143484451","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143484451?lang=zh_cn&edition=full","pubTime":"2026-08-06 06:10","pubTimestamp":1785967839,"startTime":"0","endTime":"0","summary":"\\n\\n公司同日宣布，Richard Arthur Moscicki 博士获委任为独立非执行董事、薪酬委员会主席及审核委员会成员，生效日期同为2026年8月5日。\\n\\n根据服务协议，Moscicki 博士任期自生效日起至公司下届股东周年大会届满，届时可按公司组织章程细则获重选连任；若重选成功，任期将再延续三年。\\n\\n截至公告日，公司董事会由执行董事薛群博士；非执行董事赵瑋女士、王廷伟先生；独立非执行董事Richard Arthur Moscicki 博士、James Arthur Geraghty先生、陈炳钧先生及胡澜博士组成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123773592","title":"北海康成-B特别股东大会普通决议案获全票通过","url":"https://stock-news.laohu8.com/highlight/detail?id=1123773592","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123773592?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:22","pubTimestamp":1785752576,"startTime":"0","endTime":"0","summary":"北海康成-B8月3日公告，2026年8月3日举行的股东特别大会已全票通过一项普通决议案，同意批准、追认及确认与药明生物签订的服务采购框架协议及其年度上限，并授权董事办理相关事宜。投票结果显示，赞成票201,307,108股，占出席并有表决权股份的100%；反对票0股，占比0%。其中，药明生物间接持有96,859,693股，占已发行股本约16.21%，并已按上市规则在会议中放弃投票。因此，本次可投票股份总数为500,583,654股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655820269","title":"北海康成-B：戈芮宁出海北非市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2655820269","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655820269?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:47","pubTimestamp":1785404820,"startTime":"0","endTime":"0","summary":"7月30日，北海康成-B（01228）发布公告，公司已全面启动戈芮宁（注射用维拉苷酶β）在北非市场的注册程序及商业化准备工作。戈芮宁于2025年5月15日获得中国国家药品监督管理局的上市批准，成为中国首个本土自主研发的I型及III型戈谢病患者的长期酶替代疗法。戈芮宁出海北非市场是布局全球戈谢病市场的重要里程碑，预计将提高北非患者的治疗可及性，并丰富公司的收益结构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607303826811957.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607303826811957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01228","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184078591","title":"北海康成-B启动戈芮寧出海北非注册与商业化准备","url":"https://stock-news.laohu8.com/highlight/detail?id=1184078591","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184078591?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:26","pubTimestamp":1785403575,"startTime":"0","endTime":"0","summary":"北海康成-B（01228）7月30日公告称，已全面启动旗下自主研发产品戈芮寧（注射用维拉苷酶β）在北非重点市场的注册程序及商业化筹备工作，相关上市准备正有序推进。\n戈芮寧已于2025年5月15日获中国国家药品监督管理局批准上市，适用于12岁及以上青少年与成人I型及III型戈谢病患者的长期酶替代疗法。该产品为中国首个本土自主研发的同类疗法，北海康成-B拥有其全球开发及商业化专有权利。\n公司正进行一项获国家药监局批准的注册临床试验，计划将戈芮寧的适用人群扩展至2岁至12岁儿童。\n截至公告日期，公司尚未在北非市场录得戈芮寧的正式销售收益，相关卫生监管机构的注册程序仍在进行中。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192558564","title":"北海康成-B启动戈润在非洲北部市场的注册及上市筹备工作","url":"https://stock-news.laohu8.com/highlight/detail?id=1192558564","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192558564?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:24","pubTimestamp":1785403484,"startTime":"0","endTime":"0","summary":"北海康成-B正式宣布，已着手启动戈润产品于北非市场的注册流程与上市准备工作。这一战略举措标志着该公司正加速布局海外新兴市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655827576","title":"北海康成-B(01228.HK)已全面启动戈芮宁于北非重点市场的注册程序及商业化筹备工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2655827576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655827576?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:23","pubTimestamp":1785403383,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01228","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174725577","title":"北海康成-B（01228）将于2026年8月3日线上召开股东特别大会审议与药明生物服务采购框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1174725577","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174725577?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:22","pubTimestamp":1784125344,"startTime":"0","endTime":"0","summary":"北海康成-B7月15日公告，公司拟于2026年8月3日09:00以线上方式召开股东特别大会，就与药明生物有关的服务采购框架协议及其年度上限进行审批、追认及确认，并授权董事会成员办理相关事宜。\\n\\n根据公告，股东如欲在股东特别大会上行使表决权，须通过委任大会主席为受委代表并在指定时限内递交代表委任表格。以印刷或电子形式提交代表委任表格的截止时间均为2026年8月1日09:00。凡于2026年8月3日名列股东名册的股东，有权出席并投票。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197436234","title":"北海康成-B（01228）延迟寄发药明生物服务采购框架协议通函","url":"https://stock-news.laohu8.com/highlight/detail?id=1197436234","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197436234?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:36","pubTimestamp":1783586207,"startTime":"0","endTime":"0","summary":"北海康成-B7月9日公告称，公司原计划在2026年6月16日公告发布后15个营业日内向股东寄发有关与药明生物技术有限公司订立之服务采购框架协议的通函。由于公司需要额外时间编制并落实通函所载资料，寄发日期将延迟至2026年7月20日或之前。 董事会函件，说明服务采购框架协议及拟进行交易的详情与年度上限；","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649625477","title":"Baheal Wellness Industry International Trading Limited增持北海康成-B(01228.HK)305.7万股 每股作价约2.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649625477","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649625477?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:48","pubTimestamp":1783334934,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102060145","title":"北海康成-B更新2026年6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1102060145","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102060145?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:55","pubTimestamp":1783068907,"startTime":"0","endTime":"0","summary":"北海康成制药有限公司于2026年7月3日发布了截至2026年6月30日的证券变动月报表。报告显示，公司本月无新增普通股发行或库藏股变动，已发行股份总数维持在597,443,347股，库存股份数为0股，表明股份数目无变化。公司法定/注册股本依旧为5,000,000,000股，面值每股USD 0.00001，金额合计USD 50,000。根据本次披露，公司在2026年6月期间的股本维持不变，各项权益事务均受到香港联交所《上市规则》及相关法律法规的规范与监督。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185636720","title":"北海康成-B更新5月股份变动月报表，已发行股本增至5.97亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1185636720","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185636720?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:36","pubTimestamp":1782981366,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司于2026年7月2日发布截至2026年5月31日的股份变动月报表。报告期内，公司法定/注册股本维持在5,000,000,000股，面值每股0.00001美元，法定/注册股本总额为50,000美元，无增减变化。本月无股份购回或注销活动。此外，首发前股权激励计划保留了20,695,760股的潜在发行额度。截至本月末，公司确认其已符合适用的公众持股量要求。据公告披露，本次月报由公司董事长薛群博士签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195191655","title":"北海康成-B5月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1195191655","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195191655?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:37","pubTimestamp":1780562251,"startTime":"0","endTime":"0","summary":"2026年6月4日，北海康成制药有限公司公布截至2026年5月31日止的证券变动月报。报告显示，公司法定注册股本总额为5,000,000,000股，每股面值USD 0.00001，法定注册股本USD 50,000，与上月保持一致。报告期内，公司已发行股份总数为595,443,347股，无任何库藏股份，未发生新增发行、回购或注销事宜，股本结构总体保持不变。“首次公开发售前股权激励计划”及“首次公开发售后受限制股份单位计划”当月均无新股发行。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194206845","title":"北海康成-B拟回购不超过已发行股本10%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1194206845","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194206845?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:46","pubTimestamp":1780393569,"startTime":"0","endTime":"0","summary":"北海康成-B于港交所发布公告，董事会建议在股东周年大会上寻求授权，回购不超过公司已发行股份总数10%的股份。董事会认为实施股本回购符合公司及股东的整体最佳利益。公告同时披露，自2025年6月至2026年5月，北海康成-B股价于港交所的最高交易价约为3.50港元，最低交易价约为0.14港元。董事会表示，上述交易将视公司资本状况与市况而定，若行使回购授权后影响营运资金或资本结构，将审慎评估行使安排。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"北海康成-B拟回购不超过已发行股本10%的股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638508174","title":"18倍“奇迹”仅4个月便腰斩，北海康成-B(01228)陷入戴维斯双杀？","url":"https://stock-news.laohu8.com/highlight/detail?id=2638508174","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638508174?lang=zh_cn&edition=full","pubTime":"2026-05-27 16:37","pubTimestamp":1779871059,"startTime":"0","endTime":"0","summary":"5月26日，北海康成-B股价大跌超10%，盘中最低价触及1.66港元，刷新年内新低，也让北海康成的股价回到去年8月12日公告宣布与百洋医药签订独家合作协议之前。2025年，港股医药板块涌现出一批“三倍股”、“四倍股”，但北海康成依旧能够凭借1824.81%的年度涨幅从其中脱颖而出。然而，反转发生在北海康成披露2025年报之后。根据北海康成在今年3月30日披露的2025年报，公司当期收入为4998.3万元，同比减少41.27%;净利润1481.8万元，同比扭亏为盈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"18倍“奇迹”仅4个月便腰斩，北海康成-B(01228)陷入戴维斯双杀？","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01228","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194435589","title":"北海康成-B4月股份变动月报：股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1194435589","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194435589?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:51","pubTimestamp":1778064713,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司于2026年5月6日发布截至2026年4月30日的股份变动月报。报告显示，公司本月股本维持稳定，具体情况如下：。北海康成製藥有限公司目前注册股本为5,000,000,000股普通股，每股面值为USD0.00001，注册股本总额USD50,000。截至4月30日，已发行股份总数为595,443,347股，与上月底持平；库存股份数量为0股。期间不存在新增发行、购回或注销情况。公司表示，已符合香港联交所相关规则要求，并确认公司持股量满足公众持股比例。公告由董事长薛群博士签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144970909","title":"北海康成-B2025年收入下滑逾四成但成功扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1144970909","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144970909?lang=zh_cn&edition=full","pubTime":"2026-04-29 22:00","pubTimestamp":1777471233,"startTime":"0","endTime":"0","summary":"北海康成制药有限公司注册于开曼群岛，主要聚焦罕见病及肿瘤创新药物的临床开发与商业化，并在中国内地、香港及台湾等地专注于相关基因及生物制剂、小分子、基因疗法等多元化产品管线的布局和合作开发。经调整后，2025年度亏损为80.4百万元，较上年同期明显下降。2025年度，北海康成-B在收入同比下降的背景下，通过终止部分海外租赁、削减经营和研发开支等举措，实现了业绩大幅改善并顺利扭亏为盈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"北海康成-B2025年收入下滑逾四成但成功扭亏为盈","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627462768","title":"北海康成-B(01228)股东将股票存入摩根士丹利香港证券 存仓市值2.55亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627462768","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627462768?lang=zh_cn&edition=full","pubTime":"2026-04-14 08:09","pubTimestamp":1776125360,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，4月13日，北海康成-B(01228)股东将股票存入摩根士丹利香港证券，存仓市值2.55亿港元，占比15.73%。北海康成发布公告，于2026年4月10日，本公司建议根据首次公开发售后购股权计划向一名购股权承授人(公司执行董事、董事会主席及首席执行官薛群博士)授出合共637.26万份购股权及根据首次公开发售后受限制股份单位计划向一名受限制股份单位承授人授出合共637.26万份受限制股份单位，均须待独立股东批准后方可作实。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2089283258.USD","BK4585","LU0106261372.USD","LU1074936037.SGD","LU2111349929.HKD","LU0234570918.USD","LU2089284900.SGD","LU0314104364.USD","LU1720051108.HKD","LU1989772840.SGD","BK4581","LU2271345857.HKD","LU0158827781.USD","LU1791710582.SGD","LU1732799900.SGD","LU1791710400.SGD","BK4534","LU1668664300.SGD","LU0795875169.SGD","LU1244550494.USD","BK4588","LU0557290698.USD","LU0971096721.USD","LU2133065610.SGD","LU0912757837.SGD","IE00BZ1G4Q59.USD","LU0320765646.SGD","BK4504","BK4127","LU0225283273.USD","01228","LU1989772923.USD","LU1720051017.SGD","LU0795875086.SGD","LU0158827948.USD","161027","LU2357305700.SGD","LU0528227936.USD","LU1244550577.SGD","LU1363072403.SGD","LU1732800096.USD","LU0106831901.USD","LU2023251221.USD","LU0267386448.USD","LU1548497426.USD","BK4516","LU0882574139.USD","LU2347655156.SGD","LU0098860793.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssitimber.com.hk","stockEarnings":[{"period":"1week","weight":0.0804},{"period":"1month","weight":0.0969},{"period":"3month","weight":-0.0652},{"period":"6month","weight":-0.3042},{"period":"1year","weight":1.1717},{"period":"ytd","weight":-0.1602}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":0.0865},{"period":"3month","weight":-0.0327},{"period":"6month","weight":-0.0388},{"period":"1year","weight":0.0249},{"period":"ytd","weight":-0.0039}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"CANbridge Pharmaceuticals Inc是一家全球生物制药公司。该公司专注于罕见病转化疗法的研究、开发和商业化。该公司拥有一个药物组合，其中包括三种获批药物和八种资产的管线，针对尚未满足需求的罕见病适应症。这些包括亨特综合征和其他溶酶体贮积症、阵发性睡眠性血红蛋白尿和其他补体介导的疾病、血友病A、代谢性疾病、罕见胆汁淤积性肝病和神经肌肉疾病。其管线包括Hunterase、Livmarli、CAN106和CAN103。Hunterase是一种酶替代疗法，用于治疗II型粘多糖贮积症（MPS II），也称为亨特综合征。Livmarli是一种口服、吸收率极低、可逆性的回肠胆汁酸转运蛋白抑制剂，正在开发中，用于治疗罕见的胆汁淤积性肝病，包括Alagille综合征和进行性家族性肝内胆汁淤积症。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.126185},{"month":2,"riseRate":0.4,"avgChangeRate":0.011895},{"month":3,"riseRate":0.2,"avgChangeRate":-0.095239},{"month":4,"riseRate":0.2,"avgChangeRate":-0.054254},{"month":5,"riseRate":0,"avgChangeRate":-0.09989},{"month":6,"riseRate":0.4,"avgChangeRate":0.271134},{"month":7,"riseRate":0.4,"avgChangeRate":0.385009},{"month":8,"riseRate":0.4,"avgChangeRate":0.207966},{"month":9,"riseRate":0.75,"avgChangeRate":0.161514},{"month":10,"riseRate":0,"avgChangeRate":-0.161874},{"month":11,"riseRate":0.25,"avgChangeRate":-0.205763},{"month":12,"riseRate":0.5,"avgChangeRate":0.059277}],"exchange":"SEHK","name":"北海康成-B","nameEN":"CANBRIDGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"北海康成-B(01228)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供北海康成-B(01228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"北海康成-B,01228,北海康成-B股票,北海康成-B股票老虎,北海康成-B股票老虎国际,北海康成-B行情,北海康成-B股票行情,北海康成-B股价,北海康成-B股市,北海康成-B股票价格,北海康成-B股票交易,北海康成-B股票购买,北海康成-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"北海康成-B(01228)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供北海康成-B(01228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}